New drug combo aims to improve stem cell collection for myeloma patients

NCT ID NCT03909412

First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 13 times

Summary

This early-phase study tests a combination of drugs (carfilzomib, cyclophosphamide, dexamethasone, and G-CSF) to collect stem cells for a transplant in people with multiple myeloma. The goal is to find the safest and most effective dose of carfilzomib. About 18 participants will be enrolled, and the study focuses on side effects and how well the stem cells are collected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hackensack Meridian Health - John Theurer Cancer Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.